Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

150.73 -4.12 (-2.66%)

Streaming Delayed Price Updated: 12:11 PM EDT, Mar 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

55 56 Next >

Novartis Ag (NVS) Q3 2024 Earnings Call Transcript ↗

October 29, 2024

NVS earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook ↗

October 29, 2024

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

Via Benzinga

Topics Earnings

Novartis Reports Q3 Momentum, But Shares Lose Support ↗

October 29, 2024

Novartis stock slipped Tuesday, despite a solid Q3 performance and an upgraded outlook.

Via Investor's Business Daily

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis ↗

October 28, 2024

The companies will collaborate on a molecular glue degrader, a potential treatment for autoimmune diseases.

Via Investor's Business Daily

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments”

October 28, 2024

Via AB Newswire

Topics Artificial Intelligence

Looking Into Novartis's Recent Short Interest ↗

October 14, 2024

Via Benzinga

Why NYSE:NVS is a Top Pick for Dividend Investors. ↗

October 09, 2024

Exploring NOVARTIS AG-SPONSORED ADR (NYSE:NVS)'s dividend characteristics.

Via Chartmill

Balancing Dividends and Fundamentals: The Case of NYSE:NVS. ↗

September 13, 2024

Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals.

Via Chartmill

Why Is Monte Rosa Therapeutics Stock Surging On Monday? ↗

October 28, 2024

Monte Rosa Therapeutics stock rises as it announces a global licensing deal with Novartis to advance MRT-6160 for immune conditions.

Via Benzinga

3 Absurdly Cheap Stocks That Pay High Dividends ↗

October 24, 2024

These stocks are trading at less than 15 times their expected future profits.

Via The Motley Fool

After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent ↗

October 18, 2024

Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,...

Via Benzinga

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer ↗

October 18, 2024

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a significant reduction in cancer recurrence in a Phase 3 trial. European...

Via Benzinga

1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move ↗

October 17, 2024

Novartis is taking a more calculated and strategic approach to its growth.

Via The Motley Fool

Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch ↗

October 16, 2024

William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales...

Via Benzinga

2 Magnificent Dividend Stocks to Buy and Hold Forever ↗

October 14, 2024

These companies have compelling track records.

Via The Motley Fool

Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm ↗

October 10, 2024

OnKure Therapeutics has garnered attention following its merger with Reneo Pharmaceuticals and a $65 million private placement. Oppenheimer initiated coverage with an Outperform rating, highlighting...

Via Benzinga

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

October 03, 2024

Via Investor Brand Network

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

October 03, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

Via FinancialNewsMedia

Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear ↗

October 03, 2024

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

Via Investor's Business Daily

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next ↗

October 01, 2024

HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...

Via Benzinga

Topics Economy

The Importance of Managing Bad Cholesterol: What You Should Know

September 27, 2024

(BPT) - Sponsored by Novartis Pharmaceuticals Corporation

Via Brandpoint

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

September 24, 2024

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END

Via FinancialNewsMedia

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

September 24, 2024

From FN Media Group LLC

Via GlobeNewswire

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

September 20, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END

Via FinancialNewsMedia

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗

September 19, 2024

Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.

Via Investor's Business Daily

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

September 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets ↗

September 18, 2024

Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist...

Via Benzinga

Topics Intellectual Property

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years ↗

September 18, 2024

Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...

Via Benzinga

Time To Invest And Or Trade In Bio-Tech Stocks? ↗

September 13, 2024

Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...

Via Talk Markets

Topics ETFs

This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday ↗

September 11, 2024

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.